Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Home Print this page Email this page
Users Online: 26

 Table of Contents  
Year : 2013  |  Volume : 10  |  Issue : 4  |  Page : 24-25

Thyroid dysfunction and the heart

Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India

Date of Web Publication2-Feb-2013

Correspondence Address:
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-0354.106818

Rights and Permissions

How to cite this article:
Ariachery A. Thyroid dysfunction and the heart. Thyroid Res Pract 2013;10, Suppl S1:24-5

How to cite this URL:
Ariachery A. Thyroid dysfunction and the heart. Thyroid Res Pract [serial online] 2013 [cited 2023 Feb 1];10, Suppl S1:24-5. Available from: https://www.thetrp.net/text.asp?2013/10/4/24/106818

  Introduction Top

Thyroid hormones are required for a variety of metabolic and developmental processes. Heart is one of the target organs for thyroid hormone action. Overt thyroid dysfunction is associated with increased cardiac morbidity. Therefore, thyroid dysfunction is considered to be a modifiable risk factor for those who are at increased risk of cardiovascular disease. [1]

Thyroid hormone influences cardiac performance by genomic and non genomic effects. [2],[3],[4],[5],[6] It regulates cardiac output by affecting stroke volume and heart rate. Several cardiac proteins are transcriptionally regulated by T3. It also regulates transcription of pacemaker related genes and angiotensin receptors in vascular smooth muscle cells. The non genomic effects include transport of ions (calcium, sodium and potassium) across plasma membrane, glucose and amino acid transport, mitochondrial function and a variety of intracellular signaling pathways. Thyroid hormones have a proangiogenic effect in adult heart and this occurs via both non genomic and genomic effect.

  Hyperthyroidism Top

T3 promotes relaxation of the peripheral vasculature, decrease systemic vascular resistance by its actions of vascular smooth muscle cells and endothelial nitric oxide production. There is reduction in renal perfusion pressure and activation of the rennin angiotensin aldosterone system which leads to increase in sodium absorption and blood volume. The cardiac preload (left ventricular end diastolic volume) is increased. There is increase in heart rate. This increase in heart rate, high cardiac output and decreased peripheral vascular resistance leads to a hyper dynamic circulation. Long term exposure to thyroid hormone excess may lead to increased left ventricular mass, arterial stiffness, left atrial size, diastolic dysfunction and impairment of left ventricular function. These changes are reversible as there is no cardiac fibrosis.

Heart failure is the main complication of all forms of heart disease. The American College of Cardiology has defined it as a complex syndrome that impairs the ability of the ventricle to fill with or reject blood. Patients with hyperthyroidism are at increased risk for atrial arythmias and heart failure specially in elderly patients. Patients with severe hyperthyroidism may develop high output heart failure. The clinical manifestation and severity vary depending on the age of patients, duration and severity of hyper thyroidism and presence of underlying heart disease. Patients on amiodarone induced thyrotoxicosis are at increased risk for adverse cardiac events. Association of subclinical hyperthyroidism and cardiovascular disease is not very clear.

Hypothyroidism is associated with low cardiac output due to decreased heart rate and stroke volume. Vascular function may also be deranged in hypothyroidism. There is increased cardiovascular disease risk related to coronary artery disease, cardiomyopathy and lipid disorders. [7] Some studies have suggested increased risk for cardiac death in patients with subclinical hypothyroidism. However, there is difference of opinion regarding whether the increased risk is related to the subclinical hypothyroidism or associated lipid abnormalities, metabolic syndrome etc. There is no definite evidence to document benefit of thyroxin substitution in these patients.

Heart failure is one of the major causes for mortality in developed countries. It is the final common path for most cardiac diseases. Thyroid dysfunction is considered to be one of the modifiable risk factors for heart failure. Therefore, screening for thyroid dysfunction is recommended for all patients with newly diagnosed heart failure.

  References Top

1.Klein I, Ojama K. Editorial: Thyroid hormone - Targeting the heart. Endocrinology 2001;142:11-2.  Back to cited text no. 1
2.Dillmann WH. Biochemical basis of thyroid action in the heart. Am J Med 1990;88:626-30.  Back to cited text no. 2
3.Brent GA. Molecular basis of thyroid hormone action. N Engl J Med 1994;331:847-54.  Back to cited text no. 3
4.Davis PJ, Leonard JL, Davis FB. Mechanisms of nongenomic actions of thyroid hormone. Front Neuroendocrinol 2008;29:211-8.  Back to cited text no. 4
5.Mariash CN. To Beta or not to Beta. Thyroid 2010;20:451-2.  Back to cited text no. 5
6.Danzi S, Klein I. Thyroid hormone and the cardiovascular system. Med Clin North Am 2012;96:257-68.  Back to cited text no. 6
7.Wanjia X, Chenggang W, Aihong W, Xiaomei Y, Jiajun Z, Chunxiao Y, et al. 2012. A high normal TSH level is associated with an atherogenic lipid profile in euthyroid non smokers with newly diagnosed asymptomatic coronary heart disease. Lipids Health Dis 2012;11:44.  Back to cited text no. 7


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded278    
    Comments [Add]    

Recommend this journal